manufacturing process, the q10 will form insoluble lumps (or crystals) that are unable to pass through the intestinal barrier and enter the blood.
oxIdISEd ANd REdUcEd foRmS of coq10 coq10 occurs in the body in two forms, oxidised (ubiquinone) and reduced (ubiquinol). these forms undergo continual inter-conversion as part of the normal functioning of coq10, and neither form is more important than the other.
most people are able to sufficiently absorb coq10 in its oxidised (ubiquinone) form, and this is the form on which most randomised controlled clinical trial studies have been based.
In this regard, there have been more than 90 clinical trial studies that have used Bio-quinone coq10, confirming the bioavailability, efficacy and safety of this product.
Supplementation with the reduced (ubiquinol) form of coq10 may be beneficial in people with impaired digestive absorption, for example those with irritable bowel syndrome or the elderly.
Relatively few clinical trials have been carried out to date using the ubiquinol form of coq10. It should be noted that ubiquinol is extremely sensitive to the effect of air and light.
Some products claiming to contain ubiquinol in fact contain ubiquinone – this can be determined by cutting open the capsule; ubiquinol should be white in colour whereas ubiqinone is yellow.
Visit
www.q10.co.uk / www.q-
symbio.com /
www.kisel-10.co.uk for more information.
fURthER REAdINg: • Alehagan U et al (2013) cardiovascular mortality and N-terminal proBNP reduced after combined selenium and coq10 supplementation: a 5 year prospective randomised double blind placebo controlled trial among elderly Swedish citizens. Int J cardiol; 167:1860-1866. • Alehagan U et al (2015a) levels of sP- selectin and hs-cRP decrease with dietary intervention with selenium and coq10. PloS oNE; 10:e0137680 • Alehagan U et al (2015b) less increase of copeptin and mR-proAdm due to intervention with selenium and coq10 for 4 years- follow up results of a randomised controlled trial in elderly citizens. Biofactors; 41: 443-452. • Alehagan U et al (2015c) Reduced cardiovascular mortality 10 years after supplementaion with selenium and coq10 for 4 years: follow up results of a randomised controlled trial in elderly citizens. PloS one; 10: e0141641 • Alehagan U et al (2016) Supplementation with selenium and coq10 reduces cardiovascular mortality in elderly with low selenium status. PloS oNE; 11:e0157541. • Johansson P et al (2013) Effect of selenium and coq10 on the cardiac biomarker Nt-proBNP. Scand cardiovadc J; 1-8. • Johansson P et al (2015) Improved health related quality of life and more days out of hospital with supplementation with selenium and coq10 combined. J Nutr health Aging; 19: 870-877. • mantle d (2015) coq10 and cardiovascular disease: an overview. Br J cardiol; 22:160-166 • okuyama h et al (2015) Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Expert Rev clin Pharmacol; 8: 189-199.
PhARmAcY IN focUS - 17
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64